Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays

Within the past few years, poly (ADP-ribose) polymerase inhibitors (PARPi) have been added to the standard of care for cancer patients, mainly for those exhibiting specific genomic alterations in the homologous recombination (HR) pathway. Until now, patients who are eligible to receive PARPi have be...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Br J Cancer
Huvudupphovsmän: Morice, Pierre-Marie, Coquan, Elodie, Weiswald, Louis-Bastien, Lambert, Bernard, Vaur, Dominique, Poulain, Laurent
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group UK 2021
Ämnen:
Perspective
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8257604/
https://ncbi.nlm.nih.gov/pubmed/33767416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-021-01295-z
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk